title: Malignancy and Janus Kinase Inhibition.
abstract: The use of biologics such as anti-tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung cancer, and nonmelanoma skin cancers (NMSCs) is greater in patients with RA compared with the general population. The incidence of all malignancy (excluding NMSC) was similar in tofacitinib users compared with the general population. The rates of overall and site-specific malignancies in patients with RA treated with tofacitinib are similar to what is expected in the RA population and not different from disease-modifying antirheumatic drugs and biologics.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd, Dallas, TX 75390, USA; Division of Rheumatology, Presbyterian Hospital, 8200 Walnut Hill Ln, Dallas, TX 75231, USA; Metroplex Clinical Research Center, 8144 Walnut Hill Ln, #800, Dallas, TX 75231, USA. Electronic address: psivaraman@arthdocs.com.
authors.forename: Padmapriya
authors.initials: P
authors.lastname: Sivaraman
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd, Dallas, TX 75390, USA; Division of Rheumatology, Presbyterian Hospital, 8200 Walnut Hill Ln, Dallas, TX 75231, USA; Metroplex Clinical Research Center, 8144 Walnut Hill Ln, #800, Dallas, TX 75231, USA.
authors.forename: Stanley B
authors.initials: SB
authors.lastname: Cohen
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D009369:Neoplasms / Q000453:epidemiology; D010880:Piperidines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000453:epidemiology*
chemical_list: D018501:Antirheumatic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; D053612:Janus Kinases
keywords: Jak inhibitors; Lung cancer; Lymphoma; Malignancy; Rheumatoid arthritis; Tofacitinib